rs2230589
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 0P and 10B. BA1BP7BS2_Supporting
This summary comes from the ClinGen Evidence Repository: The NM_000215.4(JAK3):c.2625C>T (p.Leu875=) synonymous variant occurs at a high allele frequency with a filtering allele frequency based on the European non-Finnish population (upper bound of 95% CI of 1934/129188 observed alleles) is 0.01456 in gnomAD v2.1.1 which is above the SCID-VCEP threshold (>0.00447; BA1). 17 adult homozygous individuals were reported in gnomAD, BS2_Supporting (European non-Finnish n=10, South Asian n=3, European Finnish n=2, and Other n=2).The variant has been reported in one patient in the literature (Patient 17 in PMID:19203666). Patient 17 has T-B+NK- (0 CD3 T cells, 0.14x10^9 B cells/L, 0.01x10^9 NK cells/L) SCID (0.5pt) and absent IL-2–induced STAT5 phosphorylation (1pt). This combination is specific for T-B+ severe combined immunodeficiency due to JAK3 deficiency (Total 1.5pt; PP4 not considered due to high allele frequency). A confirmed deleterious γc or JAK3 variant was not identified in Patient 17, although a number of sequence variants were identified in his JAK3 gene (IVS13-30c>t/wt, c.2625C>T (L875L)/wt, IVS 20+32T>C/wt). An affected sibling of Patient 17 also carried these same variants, whereas an unaffected sibling did not (PP1 not considered due to high allele frequency). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive T-B+ SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1, BS2_Supporting, and BP7. (VCEP specifications version 1). LINK:https://erepo.genome.network/evrepo/ui/classification/CA214091/MONDO:0010938/121
Frequency
Consequence
NM_000215.4 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
JAK3 | NM_000215.4 | c.2625C>T | p.Leu875= | synonymous_variant | 19/24 | ENST00000458235.7 | |
JAK3 | XM_047438786.1 | c.2625C>T | p.Leu875= | synonymous_variant | 19/24 | ||
JAK3 | XR_007066796.1 | n.2675C>T | non_coding_transcript_exon_variant | 19/20 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
JAK3 | ENST00000458235.7 | c.2625C>T | p.Leu875= | synonymous_variant | 19/24 | 5 | NM_000215.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00963 AC: 1466AN: 152222Hom.: 11 Cov.: 32
GnomAD3 exomes AF: 0.0107 AC: 2700AN: 251480Hom.: 16 AF XY: 0.0116 AC XY: 1573AN XY: 135916
GnomAD4 exome AF: 0.0146 AC: 21407AN: 1461872Hom.: 193 Cov.: 33 AF XY: 0.0146 AC XY: 10598AN XY: 727236
GnomAD4 genome AF: 0.00960 AC: 1463AN: 152340Hom.: 11 Cov.: 32 AF XY: 0.00925 AC XY: 689AN XY: 74508
ClinVar
Submissions by phenotype
T-B+ severe combined immunodeficiency due to JAK3 deficiency Benign:3
Benign, reviewed by expert panel | curation | ClinGen Severe Combined Immunodeficiency Variant Curation Expert Panel, ClinGen | Nov 14, 2023 | The NM_000215.4(JAK3):c.2625C>T (p.Leu875=) synonymous variant occurs at a high allele frequency with a filtering allele frequency based on the European non-Finnish population (upper bound of 95% CI of 1934/129188 observed alleles) is 0.01456 in gnomAD v2.1.1 which is above the SCID-VCEP threshold (>0.00447; BA1). 17 adult homozygous individuals were reported in gnomAD, BS2_Supporting (European non-Finnish n=10, South Asian n=3, European Finnish n=2, and Other n=2). The variant has been reported in one patient in the literature (Patient 17 in PMID: 19203666). Patient 17 has T-B+NK- (0 CD3 T cells, 0.14x10^9 B cells/L, 0.01x10^9 NK cells/L) SCID (0.5pt) and absent IL-2–induced STAT5 phosphorylation (1pt). This combination is specific for T-B+ severe combined immunodeficiency due to JAK3 deficiency (Total 1.5pt; PP4 not considered due to high allele frequency). A confirmed deleterious γc or JAK3 variant was not identified in Patient 17, although a number of sequence variants were identified in his JAK3 gene (IVS13-30c>t/wt, c.2625C>T (L875L)/wt, IVS 20+32T>C/wt). An affected sibling of Patient 17 also carried these same variants, whereas an unaffected sibling did not (PP1 not considered due to high allele frequency). In summary, this variant meets the criteria to be classified as Benign for autosomal recessive T-B+ SCID based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: BA1, BS2_Supporting, and BP7. (VCEP specifications version 1). - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. - |
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jan 31, 2013 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Severe combined immunodeficiency disease Benign:1
Benign, no assertion criteria provided | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 29, 2011 | - - |
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at